The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Open accessAbstract
The blood–brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The disruption of the BBB is involved in the pathophysiology of various neurological diseases such as Alzheimer's disease (AD), 45 and traumatic brain and spinal cord injuries. 46”
From Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review (2023) · cites this paper as [45]
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Research works printed but not linked: 14
- Bernheimer H., 1973, Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415
- Dahlstrom A., 1990, J. Neural Transm. Suppl., 29, 195
- Desai B. S., 2006, Soc. Neurosci. Abstr.
- Ehrlich P., 1904, Gesammelte Arbeiten zur Immunitaetsforschung, 574
- Goldmann E., 1913, Abhandl Konigl preuss Akad Wiss, 1, 1
- Iwasaki T., 1999, J. Med. Dent. Sci., 46, 31
- Kalaria R. N., 1992, Cerebrovasc. Brain Metab. Rev., 4, 226
- Kemper E. M., 2004, Rev., 30, 415
- Larsen N., 2005, Soc. Neurosci. Abstr.
- Parachikova A., 2006, Neurobiol. Aging
- Sayre L. M., 2000, Cell. Mol. Biol. (Noisy-le-grand), 46, 731
- Simpson I. A., 2002, Diabetes Nutr. Metab., 15, 281
- Verbeek M. M., 1994, Am. J. Pathol., 144, 104
- Zipser B. D., 2006, Neurobiol. Aging;
Cited by
Sorted by citations
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,038
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Metadata
- Authors
- Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B.
- Affiliations
- Department of Pharmacology, Rush University Medical Center, Chicago IL, USA
- Rush University Medical Center (US)
- Venue
- Cell Transplantation
- Publisher
- SAGE Publications
- Published
- 2007-03
- Volume
- 16
- Issue
- 3
- Pages
- 285-299
- ISSN
- 0963-6897 (ISSN-L)
- 1555-3892
- OpenAlex
- W2316522881
- Cited by
- 339
- References
- 117
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 28 · 2023: 31 · 2022: 23 · 2021: 33 · 2020: 37 · 2019: 13 · 2018: 15 · 2017: 16 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 18 · 2012: 8
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- green
- doaj.org
- Locations
- Cell Transplantation (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5r01ns045316-03, W81XWH-04-01-0365)
- U.S. Public Health Service (012307)
- National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
- National Institute of Neurological Disorders and Stroke (NS045316)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- blood-brain barrier, Alzheimer's disease, Parkinson's disease, BBB dysfunction, tight junctions, blood-brain barrier permeability, neuroinflammation, neurodegeneration, brain drug delivery, vessel density, neurodegenerative disease therapeutics
- MeSH terms
- Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Humans, Parkinson Disease, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
